In JMML, for patients with NF1 and somatic mutations of PTPN11 and K-RAS, and for the majority of patients with somatic NRAS mutations, HSCT is recommended as the first treatment option [8]. This evidence concerns the gene KRAS and juvenile myelomonocytic leukemia.